Compare Merck & Co., Inc. (MRK) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Prospect Capital Corporation — how do they compare? Merck & Co., Inc. trades at $147.98 (market cap $363.98B), while Prospect Capital Corporation trades at $2.19 (market cap $1.12B). The key difference: Merck & Co., Inc. is far larger — about 325× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (19.27%). Which is the better fit depends on your goals.
| MRK | PSEC | |
|---|---|---|
Market Cap | $363.98B | $1.12B |
Sector | Health | Financials |
52-Week High | $156.43 | $3.05 |
52-Week Low | $77.60 | $2.11 |
Enterprise Value | $410.75B | — |
Dividend Yield | 2.3% | 19.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
PSEC trades at $2.19, down 1.79% on the day, with a bearish technical outlook and mixed analyst sentiment. The stock shows a low P/B of 0.39 and has beaten earnings estimates in recent quarters, but revenue volatility and negative net income in 2025 highlight fundamental challenges. Recent news emphasizes its high dividend yield amid portfolio concerns.
The outlook is cautious due to financial deterioration and NAV erosion risks, though the deep discount to book value and consistent dividend payments may appeal to yield-seeking investors. Key risks include declining investment income and persistent underperformance relative to analyst expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
